Usefulness of Serum HBV RNA Levels for Predicting Antiviral Response to Entecavir Treatment in Patients with Chronic Hepatitis B

Overview

Journal J Gastroenterol

Date 2025 Jan 22

PMID 39841247

Authors

Masanari Kosaka

Hatsue Fujino

Masataka Tsuge

Kenji Yamaoka

Yasutoshi Fujii

Shinsuke Uchikawa

Atsushi Ono

Eisuke Murakami

Tomokazu Kawaoka

Daiki Miki

Clair Nelson Hayes

Seiya Kashiyama

Sho Mokuda

Shinichi Yamazaki

Shiro Oka

Affiliations

Soon will be listed here.

Abstract

Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).

Methods: We studied 87 CHB patients with serum HBV DNA levels ≥ 5.0 log IU/mL who initiated entecavir (ETV) treatment between 2000 and 2018. Serum HBV RNA levels were measured at three-time points: before ETV treatment, at 12 weeks, and at 48 weeks after starting ETV treatment. Clinical markers associated with the antiviral effects of ETV treatment were analyzed.

Results: Serum HBV RNA levels decreased in both HBeAg-positive and -negative patients during the observation period. In HBeAg-positive patients, multivariable analysis showed that lower HBV RNA levels at 48 weeks of ETV treatment were independently associated with HBeAg seroconversion. Additionally, lower baseline HBV RNA levels significantly predicted virologic response in those patients. In contrast, among HBeAg-negative patients, lower HBV core-related antigen (HBcrAg) levels and the FIB-4 index were independently associated with virologic response. In HBeAg-positive patients, those with higher baseline HBV RNA levels showed a more significant reduction in hepatitis B surface antigen levels.

Conclusion: Serum HBV RNA levels predicted HBeAg seroconversion and early HBV DNA reduction in HBeAg-positive patients, while HBcrAg was significantly associated with virologic response in HBeAg-negative patients. These findings highlight the different predictive roles of HBV RNA and HBcrAg based on HBeAg status, which may provide individualized treatment strategies.

References

Iloeje U, Yang H, Chen C . Natural history of chronic hepatitis B: what exactly has REVEAL revealed?. Liver Int. 2012; 32(9):1333-41. DOI: 10.1111/j.1478-3231.2012.02805.x. View

Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P . Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000; 10(3):211-31. DOI: 10.1006/scbi.2000.0321. View

Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C . Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut. 2005; 54(8):1162-8. PMC: 1774867. DOI: 10.1136/gut.2004.054452. View

Nagaya T, Nakamura T, Tokino T, Tsurimoto T, Imai M, Mayumi T . The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev. 1987; 1(8):773-82. DOI: 10.1101/gad.1.8.773. View

Yaginuma K, Kobayashi H, Kobayashi M, Morishima T, Matsuyama K, Koike K . Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol. 1987; 61(6):1808-13. PMC: 254183. DOI: 10.1128/JVI.61.6.1808-1813.1987. View

Conjeevaram H, Lok A . Management of chronic hepatitis B. J Hepatol. 2003; 38 Suppl 1:S90-103. DOI: 10.1016/s0168-8278(02)00431-2. View

Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E . Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010; 40(1):1-7. DOI: 10.1111/j.1872-034X.2009.00633.x. View

Lee Y, Suh D, Lim Y, Jung S, Kim K, Lee H . Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43(6):1385-91. DOI: 10.1002/hep.21189. View

Pugh J, Bassendine M . Molecular biology of hepadnavirus replication. Br Med Bull. 1990; 46(2):329-53. DOI: 10.1093/oxfordjournals.bmb.a072402. View

10.

Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M . Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007; 45(5):1179-86. DOI: 10.1002/hep.21581. View

11.

Huang Y, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H . Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther. 2010; 15(2):177-84. DOI: 10.3851/IMP1508. View

12.

Su Q, Wang S, Chang T, Breitkreutz R, Hennig H, Takegoshi K . Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res. 2001; 7(7):2005-15. View

13.

Zhang W, Hacker H, Tokus M, Bock T, Schroder C . Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol. 2003; 71(1):24-30. DOI: 10.1002/jmv.10464. View

14.

Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N . Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013; 48(10):1188-204. DOI: 10.1007/s00535-012-0737-2. View

15.

Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M . Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2016; 66(2):460-462. DOI: 10.1016/j.jhep.2016.09.028. View

16.

Liu S, Zhou B, Valdes J, Sun J, Guo H . Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2018; 69(4):1816-1827. PMC: 6438723. DOI: 10.1002/hep.30325. View

17.

Huang H, Wang J, Li W, Chen R, Chen X, Zhang F . Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol. 2018; 99-100:71-78. DOI: 10.1016/j.jcv.2017.12.016. View

18.

Maasoumy B, Geretti A, Frontzek A, Austin H, Aretzweiler G, Garcia-Alvarez M . HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. Hepatol Commun. 2020; 4(7):983-997. PMC: 7327219. DOI: 10.1002/hep4.1520. View

19.

Cortese M, Riveiro-Barciela M, Tabernero D, Rodriguez-Algarra F, Palom A, Sopena S . Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. Microbiol Spectr. 2022; 10(2):e0214921. PMC: 9045303. DOI: 10.1128/spectrum.02149-21. View

20.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View